Your Article Summary
See Latest ArticlesNovogen Cash Reserves $25.4M, Phenoxodiol Receives US FDA Clearance for Phase III Human Trial
Corporate News Releases - The Healthcare Sales & Marketing Network, 08/28/06
Pharmaceutical company Novogen Limited, has ended the 2005/06 financial year with solid cash reserves and US Food and Drug Administration (FDA) clearance for the final phase of human clinical testing of its lead anti-cancer drug, phenoxodiol. Revenue for the year ended 30 June, 2006, was $13.9 million, a 3.2 percent improvement over the previous corresponding period of $13.4 million
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09